2025 연구자 정보 (1 / 654)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Antozzi, Carlo (Antozzi, C) |
제1저자 |
Fdn IRCCS Carlo Besta Neurol Inst, Neuromuscular Dis & Neuroimmunol Unit, Milan, Italy IRCCS Carlo Besta Neurol Inst Fdn, Apheresis & Immunotherapy Unit, Milan, Italy |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | |
|
Arai, Yasuaki (Arai, Y) |
Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo, Japan |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Bouattour, Mohamed (Bouattour, M) |
Hop Beaujon, AP HP, Liver Canc & Innovat Therapy, Paris, France |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Breder, Valeriy V. (Breder, VV) |
NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Bril, Vera (Bril, V) |
Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON, Canada |
ABA-6509-2020 BRIL, vera |
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Chan, Stephen L. (Chan, SL) |
Chinese Univ Hong Kong, Prince Wales Hosp, Sir Yue kong Pao Ctr Canc, Dept Clin Oncol, Hong Kong, Peoples R China |
F-9149-2011 Chan, Stephen |
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Chiu, Chang-Fang (Chiu, CF) |
China Med Univ Hosp, Canc Ctr, Dept Internal Med, Taichung, Taiwan China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung, Taiwan |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Chuken, Yamil Alonso Lopez (Chuken, YAL) |
I Can Oncol Ctr, New Leon, Mexico |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Cohen, Gordon J. (Cohen, GJ) |
AstraZeneca, Global Med Dev, Gaithersburg, MD USA |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
De Bleecker, Jan (De Bleecker, J) |
Ghent Univ Hosp, Dept Neurol, Ghent, Belgium |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Erinjeri, Joseph P. (Erinjeri, JP) |
Mem Sloan Kettering Canc Ctr, Intervent Radiol Serv, New York, NY USA |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Escobar, Jose (Escobar, J) |
Hosp San Lucas Cardiol Sureste, Chiapas, Mexico |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Farmakidis, Constantine (Farmakidis, C) |
Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS USA |
AAX-6847-2020 Farmakidis, Constantine |
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Grudniak, Mariusz (Grudniak, M) |
Ctr Med NeuroProtect, Warsaw, Poland |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Heo, Jeong (Heo, J) |
Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Busan, South Korea Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea Pusan Natl Univ, Dept Internal Med, Coll Med, Busan, South Korea |
MHQ-1390-2025 Heo, Jeong |
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study [JCR상위 9.9%] Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study) |
SCIE | 0.2 |
MEDICINE, GENERAL & INTERNAL INFECTIOUS DISEASES |
bsangro@unav.es limys@amc.seoul.kr fish6069@gmail.com |
페이지 이동: